The Clinical and Experimental Therapeutics Program (Program 4) is a cohesive, integrated program supported by $7,523,204 (annual direct costs) in peer-reviewed funding, with $3,613,675 from the NCI. There are 47 members representing nine departments. Of the total 747 member peer-reviewed publications during the current grant cycle, 216 (29%) represent intraprogrammatic, and 145 (19%) represent interprogrammatic collaborations. The overall goal of the Program is to foster interaction between basic and clinical investigators that will result in innovative and effective therapies for cancer patients. The translational nature of much of the work emanating from this program and the leadership role assumed by many program faculty in studies conducted by national clinical trials cooperative groups illustrates the impact of this program in developing new therapies for oncology. The Program has a long-standing focus on drug development at all phases of clinical testing and a strong pharmacogenetic component. Trials span the gamut from preclinical development to investigator-initiated Phase I clinical trials, to Phase II trials in the regional Phase II network to Phase III studies within CALGB. They incorporate correlative laboratory studies including pharmacokinetic studies, genotyping studies, population pharmacology, pharmacogenetic studies, and the measurement of surrogate endpoints. Clinical trials are conducted by multidisciplinary teams comprised of a group of clinical investigators representing Medical Oncology, Radiation Oncology, Pathology, and appropriate surgical specialties. Clinical efforts focus on studies of new drugs (cytotoxic or cytostatic) with clinical and translational endpoints, modulation of current chemotherapy, sequencing of multidisciplinary treatment, organ preservation, transplantation, and treatment intensification as strategies to increase cure rates and response. Imaging, surgical, and pathology support are integrated into the Program. The scientific goals are (1) to foster interaction between basic and clinical investigators that will result in innovative and effective therapies;(2) to integrate new drugs into the development of multimodality therapies for patients with advanced solid tumors;and (3) to pursue a broad program of preclinical, translational, and clinical research in pharmacogenetics and pharmacology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-N)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Li, Gang; Montgomery, Jeffrey E; Eckert, Mark A et al. (2017) An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun 8:1775
Stoddart, Angela; Wang, Jianghong; Hu, Chunmei et al. (2017) Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel/+ MDS mouse model. Blood 129:2959-2970
Wing, Claudia; Komatsu, Masaaki; Delaney, Shannon M et al. (2017) Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy. Stem Cell Res 22:79-88
Shah, Palak; Trinh, Elaine; Qiang, Lei et al. (2017) Arsenic Induces p62 Expression to Form a Positive Feedback Loop with Nrf2 in Human Epidermal Keratinocytes: Implications for Preventing Arsenic-Induced Skin Cancer. Molecules 22:
Qiang, Lei; Sample, Ashley; Shea, Christopher R et al. (2017) Autophagy gene ATG7 regulates ultraviolet radiation-induced inflammation and skin tumorigenesis. Autophagy 13:2086-2103
Morita, Shuhei; Villalta, S Armando; Feldman, Hannah C et al. (2017) Targeting ABL-IRE1? Signaling Spares ER-Stressed Pancreatic ? Cells to Reverse Autoimmune Diabetes. Cell Metab 25:1207
Davis, Trevor L; Rebay, Ilaria (2017) Antagonistic regulation of the second mitotic wave by Eyes absent-Sine oculis and Combgap coordinates proliferation and specification in the Drosophila retina. Development 144:2640-2651
Kathayat, Rahul S; Elvira, Pablo D; Dickinson, Bryan C (2017) A fluorescent probe for cysteine depalmitoylation reveals dynamic APT signaling. Nat Chem Biol 13:150-152
Hu, Xue; Li, Li; Yu, Xinyi et al. (2017) CRISPR/Cas9-mediated reversibly immortalized mouse bone marrow stromal stem cells (BMSCs) retain multipotent features of mesenchymal stem cells (MSCs). Oncotarget 8:111847-111865
Hasan, Yasmin; Waller, Joseph; Yao, Katharine et al. (2017) Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States. Breast Cancer Res Treat 162:317-328

Showing the most recent 10 out of 613 publications